Ana Clara B Marini1, Reika D Motobu1, Ana T V Freitas1, João F Mota1, Benjamin T Wall2, Claude Pichard3, Alessandro Laviano4, Gustavo Duarte Pimentel1. 1. Clinical and Sports Nutrition Research Laboratory (Labince), Faculty of Nutrition, Federal University of Goias, Goiânia, GO, Brazil. 2. Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, Exeter, UK. 3. Clinical Nutrition, Geneva University Hospital, Geneva, Switzerland. 4. Department of Clinical Medicine, Sapienza University, Viale dell'Università 37, 00185, Rome, Italy.
Abstract
BACKGROUND:Creatine supplementation has been proposed to alleviate muscle loss in various populations, but has not been investigated in hemodialysis (HD) patients. Thus, our objective was to evaluate whether creatine supplementation could attenuate the loss of lean body mass (LBM) and malnutrition-inflammation score (MIS) in HD patients. METHODS: A randomized, placebo-controlled, double blind, parallel-design study included HD patients, of both sexes, aged 18-59 years. The patients were allocated to a Placebo Group (PG; n = 15; received maltodextrin, 1st week: 40 g/day and 2nd-4th weeks: 10 g/day) and a Creatine Group (CG; n = 15; received creatine plus maltodextrin, 1st week: 20 g/day of creatine plus 20 g/day of maltodextrin and 2nd-4th weeks: 5 g/day of creatine plus 5 g/day of maltodextrin). Pre and post the intervention, patients were evaluated for food intake, MIS, body composition and biochemical parameters. RESULTS:CG group attenuated the MIS (Pre: 5.57 ± 0.72 vs. Post: 3.85 ± 0.47 score, P = 0.003) compared with PG (Pre: 5.71 ± 0.97 vs. Post: 5.36 ± 0.95 score, P = 0.317) (supplement × time P = 0.017, effect size: 0.964). The change of LBM was greater in CG than in PG (CG: Δ0.95 vs PG: Δ0.13 kg). At post-intervention, 28.6% of PG patients presented LBM loss and 71.4% remain stable. In contrast, 14.4% of CG patients had LBM loss, 42.8% remain stable and 42.8% gained. Food intake and quality of life did not change. CG increased the BMI and gait speed in post-compared to pre-moment, but no difference among the groups. CONCLUSION: In HD patients, four weeks of creatine supplementation may alleviate the MIS as well as attenuate the LBM loss compared to placebo.
RCT Entities:
BACKGROUND:Creatine supplementation has been proposed to alleviate muscle loss in various populations, but has not been investigated in hemodialysis (HD) patients. Thus, our objective was to evaluate whether creatine supplementation could attenuate the loss of lean body mass (LBM) and malnutrition-inflammation score (MIS) in HDpatients. METHODS: A randomized, placebo-controlled, double blind, parallel-design study included HDpatients, of both sexes, aged 18-59 years. The patients were allocated to a Placebo Group (PG; n = 15; received maltodextrin, 1st week: 40 g/day and 2nd-4th weeks: 10 g/day) and a Creatine Group (CG; n = 15; received creatine plus maltodextrin, 1st week: 20 g/day of creatine plus 20 g/day of maltodextrin and 2nd-4th weeks: 5 g/day of creatine plus 5 g/day of maltodextrin). Pre and post the intervention, patients were evaluated for food intake, MIS, body composition and biochemical parameters. RESULTS:CG group attenuated the MIS (Pre: 5.57 ± 0.72 vs. Post: 3.85 ± 0.47 score, P = 0.003) compared with PG (Pre: 5.71 ± 0.97 vs. Post: 5.36 ± 0.95 score, P = 0.317) (supplement × time P = 0.017, effect size: 0.964). The change of LBM was greater in CG than in PG (CG: Δ0.95 vs PG: Δ0.13 kg). At post-intervention, 28.6% of PGpatients presented LBM loss and 71.4% remain stable. In contrast, 14.4% of CGpatients had LBM loss, 42.8% remain stable and 42.8% gained. Food intake and quality of life did not change. CG increased the BMI and gait speed in post-compared to pre-moment, but no difference among the groups. CONCLUSION: In HDpatients, four weeks of creatine supplementation may alleviate the MIS as well as attenuate the LBM loss compared to placebo.
Authors: Daniel S March; Thomas J Wilkinson; Thomas Burnell; Roseanne E Billany; Katherine Jackson; Luke A Baker; Amal Thomas; Katherine A Robinson; Emma L Watson; Matthew P M Graham-Brown; Arwel W Jones; James O Burton Journal: Nutrients Date: 2022-04-27 Impact factor: 6.706
Authors: Adrian Post; Joëlle C Schutten; Daan Kremer; Yvonne van der Veen; Dion Groothof; Camilo G Sotomayor; Christa A Koops; Pim de Blaauw; Ido P Kema; Ralf Westerhuis; Theo Wallimann; M Rebecca Heiner-Fokkema; Stephan J L Bakker; Casper F M Franssen Journal: J Transl Med Date: 2021-03-20 Impact factor: 5.531